ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is scheduled to announce its third-quarter earnings results for 2025 on November 7, 2025, before the market opens. Analysts predict the company will report earnings of $1.74 per share, alongside revenue estimates of $211.917 million for the quarter. The earnings call is set to take place at 8:30 AM ET, providing an opportunity for investors and analysts to gain insights into the company’s performance.
The last earnings report from ANI Pharmaceuticals was released on June 8, 2025, when the company reported a loss of ($0.12) per share. At that time, ANI revealed a negative net margin of 1.37% but a positive return on equity of 25.03%, with total revenue of $64.48 million for the quarter. Analysts forecast that ANI Pharmaceuticals will achieve $4 earnings per share for the current fiscal year and maintain the same projection for the next fiscal year.
Stock Performance and Insider Transactions
As of Thursday, shares of ANI Pharmaceuticals opened at $92.62, reflecting a 2.0% decrease in value. Over the past year, the stock has fluctuated between a low of $52.50 and a high of $99.50. The company’s current financial metrics include a debt-to-equity ratio of 1.39, a current ratio of 2.54, and a quick ratio of 1.96. ANI Pharmaceuticals boasts a market capitalization of $2.01 billion and a P/E ratio of -120.28, with a beta of 0.54.
In recent insider activity, Chad Gassert, Senior Vice President, sold 20,000 shares of the company on August 15, 2025, for an average price of $86.97, totaling $1,739,400. Following this transaction, Gassert retains 173,226 shares valued at approximately $15,065,465.22, marking a 10.35% reduction in his holdings. The sale was reported in a legal filing with the Securities and Exchange Commission (SEC).
Additionally, Stephen P. Carey, Chief Financial Officer, sold 50,000 shares on August 12, 2025, at an average price of $86.07, for a total of $4,303,500. Post-sale, Carey holds 180,863 shares valued at $15,566,878.41, which represents a 21.66% decrease in his stake. Collectively, insiders have sold 413,830 shares valued at $36,505,378 in the last quarter, while corporate insiders now own 12.70% of the company’s stock.
Institutional Investor Activity
Recent changes in institutional investments indicate a growing interest in ANI Pharmaceuticals. CANADA LIFE ASSURANCE Co increased its stake by 1.0% during the second quarter, now holding 19,408 shares valued at $1,267,000. Similarly, Thrivent Financial for Lutherans boosted its holdings by 2.6%, acquiring an additional 321 shares, bringing its total to 12,511 shares, worth $816,000.
Other notable adjustments include UBS AM, a distinct business unit of UBS Asset Management Americas LLC, which increased its stake by 0.9%, now owning 48,322 shares valued at $3,235,000. Additionally, Advisors Asset Management Inc. entered a new position valued at approximately $28,000 and MIRAE ASSET GLOBAL ETFs HOLDINGS Ltd. raised its holdings by 4.5%, now owning 10,993 shares worth $736,000.
Overall, institutional and hedge fund investors control 76.05% of ANI Pharmaceuticals’ stock, reflecting significant confidence in the company’s future prospects. As the upcoming earnings report approaches, all eyes will be on ANI Pharmaceuticals to see if it can meet or exceed these market expectations.
